Novo Nordisk AS Class B
NOVO B: XCSE (DNK)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| @$S | LOCK|%$Y | LOCK|K@V@XT |
Even With Pricing and Competitive Pressure, Novo Nordisk's Portfolio Warrants a Wide Moat
Business Strategy and Outlook
A pioneer in diabetes care, Novo Nordisk has been in the business for over 85 years. It claims 34% of the $80 billion-plus diabetes treatment market and roughly half of the more than $15 billion insulin market. Diabetes' prevalence is expected to soar in the coming decades as a result of an increasingly overweight and aging population, and we expect Novo to maintain its wide moat as it continues to dominate in diabetes and obesity therapy innovation.
United States